Premium
ADC Therapeutics SA (ADCT)
NYSE
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602,... ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.01 | 0.617283950617 | 1.62 | 1.77 | 1.6 | 410906 | 1.65334379 | CS |
| 4 | -0.16 | -8.93854748603 | 1.79 | 1.825 | 1.39 | 499875 | 1.62160559 | CS |
| 12 | -0.665 | -28.9760348584 | 2.295 | 3.49 | 1.39 | 986487 | 2.26153958 | CS |
| 26 | -1.26 | -43.598615917 | 2.89 | 3.49 | 1.39 | 641662 | 2.46479904 | CS |
| 52 | -3.07 | -65.3191489362 | 4.7 | 5.38 | 1.39 | 645250 | 3.15485732 | CS |
| 156 | -13.48 | -89.2124420913 | 15.11 | 17.28 | 0.359908 | 544063 | 3.40521637 | CS |
| 260 | -28.37 | -94.5666666667 | 30 | 56.5899 | 0.359908 | 431653 | 8.79182393 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
